A Word to the Wise About Intranasal Esketamine

Affiliations

Editorial

Alan F Schatzberg. Am J Psychiatry. 2019.

. 2019 Jun 1;176(6):422-424.

doi: 10.1176/appi.ajp.2019.19040423. Epub 2019 May 21.

No abstract available

Keywords: Depression; Esketamine; Ketamine.

Comment in

Comment on a Word to the Wise About Intranasal Esketamine.
Drevets WC, Singh JB, Hough D, Daly EJ, Popova V, Manji H. Drevets WC, et al. Am J Psychiatry. 2019 Oct 1;176(10):856-857. doi: 10.1176/appi.ajp.2019.19070688. Am J Psychiatry. 2019. PMID: 31569984 No abstract available.
More Thoughts on Intranasal Esketamine: Response to Drevets et al.
Schatzberg AF. Schatzberg AF. Am J Psychiatry. 2019 Oct 1;176(10):858-859. doi: 10.1176/appi.ajp.2019.19070688r. Am J Psychiatry. 2019. PMID: 31569985 No abstract available.
Esketamine and the Need for a New Type of Registry for Drugs With Abuse Potential.
McShane R, Baldwin DS, McAllister-Williams RH, Stone JM, Taylor D, Winstock AR, Young AH. McShane R, et al. Am J Psychiatry. 2019 Nov 1;176(11):966. doi: 10.1176/appi.ajp.2019.19060631. Am J Psychiatry. 2019. PMID: 31672039 No abstract available.

Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
Popova V, Daly EJ, Trivedi M, Cooper K, Lane R, Lim P, Mazzucco C, Hough D, Thase ME, Shelton RC, Molero P, Vieta E, Bajbouj M, Manji H, Drevets WC, Singh JB. Popova V, et al. Am J Psychiatry. 2019 Jun 1;176(6):428-438. doi: 10.1176/appi.ajp.2019.19020172. Epub 2019 May 21. Am J Psychiatry. 2019. PMID: 31109201 Clinical Trial.